Literature DB >> 27298420

International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework.

Daniel C Malone1, Nancy S Berg2, Karl Claxton3, Louis P Garrison4, Maarten IJzerman5, Kevin Marsh6, Peter J Neumann7, Mark Sculpher3, Adrian Towse8, Carin Uyl-de Groot9, Milton C Weinstein10.   

Abstract

Mesh：

Year:  2016        PMID： 27298420     DOI： 10.1200/JCO.2015.64.4328

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Targeted therapies for renal cell carcinoma.

Authors:  Edwin M Posadas; Suwicha Limvorasak; Robert A Figlin
Journal:  Nat Rev Nephrol       Date:  2017-07-10       Impact factor: 28.314

2.  New Expensive Anticancer Agents: Which Role Is Played by Quality-Adjusted Life-Years in the Selection of a Specific Treatment?

Authors:  Andrea Messori
Journal:  J Glob Oncol       Date:  2016-08-10

Review 3.  Value-based medicine in oncology: the importance of perspective in the emerging value frameworks.

Authors:  Alessandro Gonçalves Campolina
Journal:  Clinics (Sao Paulo)       Date:  2018-12-10       Impact factor: 2.365

Review 4.  Efficacy of complementary and integrative medicine on health-related quality of life in cancer patients: a systematic review and meta-analysis.

Authors:  Wan-Fu Lin; Mao-Feng Zhong; Qing-Hui Zhou; Yu-Ren Zhang; Huan Wang; Zhi-Hao Zhao; Bin-Bin Cheng; Chang-Quan Ling
Journal:  Cancer Manag Res       Date:  2019-07-22       Impact factor: 3.989

5.  Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden.

Authors:  Aris Angelis
Journal:  MDM Policy Pract       Date:  2018-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.